Kali Anne Koziol, PA-C

Kali Koziol practices at UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health.

Kali Koziol's NPI, 1356956460, was assigned on September 15, 2020. Kali Koziol holds California license 58148.

Kali Koziol's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights, at 505 Parnassus Ave, Box 0296, San Francisco, CA 94143 in San Francisco County. The practice phone is (415) 353-2733.

Kali Koziol's primary practice is UCSF Helen Diller Medical Center at Parnassus Heights in San Francisco, California, part of University of California Health. The medical group on file is UCSF Pediatrics. Dmand AI also links Kali Koziol to 5 more group practices and clinics and 4 medical groups, each named with a free account.

Dmand AI tracks the electronic health record (EHR) system at each site where Kali Koziol practices, 6 sites in all. Vendor and product names are available with a free account.

Surgical is Kali Koziol's primary specialty in the NPI Registry, under taxonomy code 363AS0400X. Kali Koziol is licensed in California.

Dmand AI lists ear eustachian tube disorders, larynx and vocal cord disease, swimmer's ear, tinnitus and vertigo among the conditions Kali Koziol treats.

CMS data shows 593 Medicare services from Kali Koziol across 8 procedure codes in 2024, for 206 Medicare patients. Medicare paid $28,071 for them. Every service was in an office.

CMS counts 206 Medicare patients who saw Kali Koziol in 2024. The largest group is 65 to 74, with 95 patients. 66% of them have high cholesterol, and 58% have high blood pressure. 35% are also on Medicaid. Their average risk score is 1.26, where 1.00 is the Medicare average.

Across all payers, Dmand AI patient panel data puts Kali Koziol's median patient age at 73, with 52% women.

In 2024, Kali Koziol wrote 329 Medicare Part D claims for 155 patients. 87% of them were for generic drugs. CMS names the drug for 234 of them, across 10 drugs with 11 or more claims each, at $21,304 in total drug cost.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 87 out of 100 for Kali Koziol for performance year 2024, reported as part of a group. Kali Koziol accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Kali Koziol as offering telehealth.

CMS Open Payments shows 2 general payments to Kali Koziol from 2 drug and device companies in 2024. Food and beverage make up the largest share, 100% of the total. Abbvie Inc. paid the most, $120.